Search

Corvus Pharmaceuticals Inc

Fermé

12.22 -5.49

Résumé

Variation du prix de l'action

24h

Actuel

Min

12.14

Max

12.99

Chiffres clés

By Trading Economics

Revenu

-4.3M

-18M

BPA

-0.19

Employés

37

EBITDA

-5.3M

-17M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+127.8% upside

Dividendes

By Acuity

Prochains Résultats

3 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-21M

1.1B

Ouverture précédente

17.71

Clôture précédente

12.22

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 sept. 2026, 23:56 UTC

Correlated Moves

EnerSys is trading higher in after-market hours, reflecting broader gains in the Nasdaq 100 Index following the Federal Reserve's rate hike decision.

16 sept. 2026, 23:56 UTC

Atomera Inc is trading modestly lower in after-hours activity, retracing from a peak shortly after the market closed on Wednesday.

16 sept. 2026, 23:56 UTC

Correlated Moves

Axcelis Technologies Inc is trading modestly higher in after-market hours, influenced by a broader upward trend in the Nasdaq 100 Index following the Fed's rate hike.

16 sept. 2026, 23:56 UTC

Reliance Inc is trading slightly lower in after-market hours, continuing a downward trend since Wednesday's close and fluctuating near the lower end of its one-month range.

16 sept. 2026, 23:56 UTC

Correlated Moves

Rockwell Automation Inc is trading slightly higher in after-market hours following the Federal Reserve's 25 basis point rate hike amid inflation concerns.

16 sept. 2026, 23:56 UTC

Norfolk Southern Corp's shares declined in after-market trading, moving lower from a post-close high and indicating unusual weakness for this time of day.

16 sept. 2026, 23:56 UTC

Correlated Moves
News

Cohu Inc's stock rose during after-market hours, buoyed by a slight increase in the Nasdaq 100 Index amid macroeconomic developments and ongoing governance discussions.

16 sept. 2026, 23:56 UTC

Correlated Moves

Columbia Financial Inc declined in after-market trading, influenced by NBT Bancorp Inc's slight decrease, settling below its previous close.

16 sept. 2026, 23:56 UTC

Correlated Moves

SkyWest Inc's shares are roughly flat in after-market trading, stabilizing near unchanged levels following earlier losses and aligning with routine trading patterns.

16 sept. 2026, 23:56 UTC

Correlated Moves

FormFactor Inc is trading higher in after-market hours, reflecting gains in the Nasdaq 100 Index following the Federal Reserve's rate hike decision.

16 sept. 2026, 23:56 UTC

UGI Corp is declining in after-market trading, positioned near its lowest cumulative return for the day after a brief recovery earlier in the session.

16 sept. 2026, 23:56 UTC

BJ's Restaurants Inc. is trading slightly lower in after-market hours, finishing down for three consecutive sessions and remaining below its 20-day moving average.

16 sept. 2026, 23:56 UTC

New Fortress Energy Inc gained in after-market trading on Wednesday, rebounding from earlier session lows after a month of underperformance.

16 sept. 2026, 23:56 UTC

Waste Management Inc. is trading modestly higher in after-market hours following a slight decline since Wednesday's close, remaining below its 20-day moving average.

16 sept. 2026, 23:56 UTC

News

T-Mobile US Inc appointed Jessica Uhl as CFO Designate, succeeding Peter Osvaldik, as the stock remained roughly flat in after-market trading.

16 sept. 2026, 23:56 UTC

Macro News

The U.S. Federal Reserve raised interest rates by a quarter-point, impacting energy markets, while natural gas prices remain roughly flat today.

16 sept. 2026, 23:56 UTC

TG Therapeutics Inc is trading lower in after-market hours, retracing from an initial high shortly after the market closed, despite remaining above its 20-day moving average.

16 sept. 2026, 23:52 UTC

MannKind Corp is seeing higher after-market trading, reflecting broader market gains despite concerns over TIC outflows and rising Treasury yields.

16 sept. 2026, 23:52 UTC

General Motors Co is trading modestly lower in after-market hours, remaining below its 20-day moving average after a recent trend of lower daily closes.

16 sept. 2026, 23:52 UTC

Correlated Moves

Corning Inc is advancing in after-market trading, supported by positive retail sales data and broader market trends, despite a $27.9B outflow in TIC flows.

16 sept. 2026, 23:51 UTC

Correlated Moves

Chimera Investment Corp is trading modestly higher in after-market hours, potentially influenced by AGNC's inclusion in the S&P MidCap 400 Index.

16 sept. 2026, 23:51 UTC

Correlated Moves
News
Social Media

NVIDIA shares rose in after-market trading as CEO Jensen Huang discussed AI safety at Dreamforce, coinciding with Salesforce's Koa CRM model announcement.

16 sept. 2026, 23:51 UTC

Viavi Solutions Inc is trading higher in after-market hours, following strong U.S. retail sales data, despite concerns over TIC flows and rising Treasury yields.

16 sept. 2026, 23:51 UTC

Dolby Laboratories Inc is rising in after-market trading, supported by stronger-than-expected U.S. retail sales data, despite concerns over $27.9B in TIC outflows.

16 sept. 2026, 23:51 UTC

Ironwood Pharmaceuticals Inc is trading modestly lower in after-market hours, positioned below its 20-day moving average and around the midpoint of its one-month trading range.

16 sept. 2026, 23:51 UTC

Correlated Moves

Northern Oil and Gas Inc is trading modestly higher in after-market hours, following strong August retail sales data that exceeded forecasts.

16 sept. 2026, 23:51 UTC

Social Media
News

Alphabet Inc. will not be required to break up its ad tech unit, and GOOGL shares rose in after-market trading following a $22B chip loan report and an analyst price target increase.

16 sept. 2026, 23:51 UTC

Rapid7 Inc is higher in after-market trading, supported by stronger-than-expected U.S. retail sales data, despite some negative sentiment from TIC flows.

16 sept. 2026, 23:51 UTC

Canadian Solar Inc is advancing in after-market hours, supported by strong U.S. retail sales for August, despite disappointing net long-term TIC flows.

16 sept. 2026, 23:51 UTC

Blue Owl Capital Corp is trading modestly higher in after-market hours, showing a recovery from earlier lows but remains near the lower end of its one-month range.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

127.8% hausse

Prévisions sur 12 Mois

Moyen 29.5 USD  127.8%

Haut 33 USD

Bas 27 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat